Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.36 |
| ▸ | POLRMT | O00411 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.30 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26027103 | 1.00 | DOT1L (0.36) | DOT1LPOLRMTRIPK1CSNK2A2CSNK2A1 | |
| SCHEMBL24606316 | 0.90 | DOT1L (0.34) | DOT1LPOLRMTRIPK1CSNK2A2CSNK2A1 | |
| SCHEMBL24606310 | 0.90 | DOT1L (0.36) | DOT1LPOLRMTRIPK1CSNK2A2CSNK2A1 | |
| SCHEMBL24606256 | 0.89 | DOT1L (0.34) | DOT1LPOLRMTRIPK1 | |
| SCHEMBL24606309 | 0.89 | IARS1 (0.38) | DOT1LPOLRMT | |
| SCHEMBL24606280 | 0.88 | DOT1L (0.35) | DOT1LPOLRMTCSNK2A2CSNK2A1 | |
| SCHEMBL26237796 | 0.87 | CSNK2A2 (0.35) | DOT1LPOLRMTCSNK2A2CSNK2A1 | |
| SCHEMBL24606327 | 0.87 | DOT1L (0.34) | DOT1LPOLRMT | |
| SCHEMBL24606329 | 0.85 | DOT1L (0.35) | DOT1LCSNK2A2CSNK2A1 | |
| SCHEMBL26946941 | 0.85 | DOT1L (0.38) | DOT1LPOLRMTRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024054618-A1 | METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| EP-4328227-A1 | NUCLEOSIDE COMPOUND AND APPLICATION THEREOF IN THE TREATMENT OF FELINE INFECTIOUS PERITONITIS | Vigonvita Life Sciences Co., Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| WO-2023239665-A1 | METHODS FOR TREATMENT OF VIRAL INFECTIONS INCLUDING SARS-COV-2 | GILEAD SCIENCES, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023167938-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| EP-4234557-A1 | SALT OF NUCLEOSIDE ANALOG AND CRYSTAL FORM THEREOF, PHARMACEUTICAL COMPOSITION AND USE | Vigonvita Life Sciences Co., Ltd. (CN) | 2023-08-30 | — | — | EP | disclosed |
| WO-2022142477-A1 | METHODS AND MODIFIED NUCLEOSIDES FOR TREATING CORONAVIRUS INFECTIONS | SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2022-07-07 | — | — | WO | disclosed |